Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 2 - Studien 11 bis 16 von insgesamt 16
- Rekrutierung läuftA phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator’s choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma
- Rekrutierung läuftA Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2Inhibitor ABBV-453 given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple MyelomaMolekulare Marker
- Rekrutierung läuftProspektives, akademisches, translationales Forschungs-Netzwerk zur Optimierung der onkologischen Gesundheitsversorgung Qualität in der adjuvanten und der fortgeschrittenen/metastasierten Situation: Gesundheitsforschung, Pharmakogenomik, Biomarker, Gesundheitsökonomie PRAEGNANT Brustkrebs: Fortgeschritten/ MetastasierendVERSORGUNGSFORSCHUNGSSTUDIE
- Rekrutierung läuftA non-interventional study of selinexor (Nexpovio) in combination with bortezomib and dexamethasone (SVd) in patients with relapsed or refractory multiple myeloma (R/RMM) - SEATTLE -
- Rekrutierung läuft
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)
CA057-001
- Rekrutierung läuftA Phase 3 Randomized Study Comparing JNJ-79635322 andan anti-BCMA AxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma who Have Received at least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody